Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A4 synthetic analog

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 6, 2013, Pages 1029-1037

  Guilherme, Rafael F ^a   Xisto, Debora G ^a   Kunkel, Steven L ^b   Freire De lima, Célio G ^a   Rocco, Patricia R M ^a   Neves, Josiane S ^a   Fierro, Iolanda M ^c   Canetti, Claudio ^a   Benjamim, Claudia F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

ATLa; Fibrosis; Inflammation; Lipoxin; Lung

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ARGINASE; ASPIRIN TRIGGERED LIPOXIN A 4; BLEOMYCIN; COLLAGEN; COLLAGEN TYPE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; LIPOXIN A; LYMPHOTOXIN; SURFACTANT PROTEIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG LAVAGE; LUNG MECHANICS; LUNG PARENCHYMA; LUNG RESISTANCE; MACROPHAGE; MICROSCOPY; MOUSE; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION;

ANIMALS; ARGINASE; ASPIRIN; BIOLOGICAL MARKERS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYTOKINES; DISEASE MODELS, ANIMAL; LIPOXINS; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDES; PULMONARY FIBROSIS; RESPIRATORY MECHANICS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890098735     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0462OC     Document Type: Article

References (50)

1. Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis: past, present and future. Respir Med 2006;100:1871-1885.
2. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, Kollias G, Aidinis V. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS ONE 2006;1:e108.
3. American Thoracic Society. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
4. Kawanami O, Ferrans VJ, Crystal RG. Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982;46:39-53.
5. Kuhn C. The pathogenesis of pulmonary fibrosis. Monogr Pathol 1993;36:78-92.
6. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33:9-13.
7. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
8. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
9. Dury S. Treatment of idiopathic pulmonary fibrosis. Rev Mal Respir 2006;23:5S87-5S91.
10. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. Chest 1996;110:1058-1067.
11. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693-702.
12. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382.
13. Delaunois LM. Mechanisms in pulmonary toxicology. Clin Chest Med 2004;25:1-14.
14. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94.
15. Fierro IM, Serhan CN. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz J Med Biol Res 2001;34:555-566.
16. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005;73:141-162.
17. Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002;165:1531-1535.
18. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 1995;92:9475-9479.
19. Kowal-Bielecka O, Kowal K, Distler O, Rojewska J, Bodzenta-Lukaszyk A, Michel BA, Gay RE, Gay S, Sierakowski S. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005;52:3783-3791.
20. McMahon B, Godson C. Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol 2004;286:F189-F201.
21. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A (4). Nat Med 2002;8:1018-1023.
22. Vachier I, Bonnans C, Chavis C, Farce M, Godard P, Bousquet J, Chanez P. Severe asthma is associated with a loss of LX4, an endogenous antiinflammatory compound. J Allergy Clin Immunol 2005;115:55-60.
23. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN. Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem 2000;275:25372-25380.
24. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A (4) and lipoxin A (4). J Pharmacol Exp Ther 2002;300:385-392.
25. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, et al. Lipoxins, aspirin-triggered epilipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002;13:2497-2507.
26. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 1999;96:8247-8252.
27. Levy BD, Serhan CN. Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered lipid mediators. Drugs Today (Barc) 2003;39:373-384.
28. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5:388-392.
29. Martins V, Valença SS, Farias-Filho FA, Molinaro R, Simões RL, Ferreira TP, E-Silva PM, Hogaboam CM, Kunkel SL, Fierro IM, et al. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009;182:5374-5381.
30. Valença SS, Da Hora K, Castro P, Moraes VG, Carvalho L, Porto LC. Emphysema and metalloelastase expression in mouse lung induced by cigarette smoke. Toxicol Pathol 2004;32:351-356.
31. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J. Myofibroblast transdifferentiation in obliterative bronchiolitis: tgf-β signaling through smad3-dependent and -independent pathways. Am J Transplant 2006;6:2080-2088.
32. Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008;58:3574-3584.
33. Trujillo G, O'Connor EC, Kunkel SL, Hogaboam CM. A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycininduced pulmonary fibrosis. Am J Pathol 2008;172:1209-1221.
34. Fonseca BP, Olsen PC, Coelho LP, Ferreira TP, Souza HS, Martins MA, Viola JP. NFAT1 transcription factor regulates pulmonary allergic inflammation and airway responsiveness. Am J Respir Cell Mol Biol 2009;40:66-75.
35. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-969.
36. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007;117:530-538.
37. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002;7:d1743-d1761.
38. Izumo T, Kondo M, Nagai A. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci 2007;80:1882-1886.
39. 4 attenuate experimental renal fibrosis. FASEB J 2011;25:2967-2979.
40. Lee TH, Crea AE, Gant V, Spur BW, Marron BE, Nicolaou KC, Reardon E, Brezinski M, Serhan CN. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis 1990;141:1453-1458.
41. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human alveolar macrophages have 15-lipoxygenase and generate 15 (S)-hydroxy-5, 8, 11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993;92:1572-1579.
42. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of antiinflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006;5:91-106.
43. Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009;158:947-959.
44. Strieter RM. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc 2008;5:305-310.
45. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C. TGF-β1 targets the GSK-3β/β- catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 2008;57:274-282.
46. Wan YY, Tian GY, Guo HS, Kang YM, Yao ZH, Li XL, Liu QH, Lin DJ. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res 2013;14:56-68.
47. Madala SK, Maxfield MD, Davidson CR, Schmidt SM, Garry D, Ikegami M, Hardie WD, Glasser SW. Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice. Pulm Med 2011;2011:653524-653535.
48. Beers MF, Solarin KO, Guttentag SH, Rosenbloom J, Kormilli A, Gonzales LW, Ballard PL. TGF-beta1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung. Am J Physiol 1998;275:L950-L960.
49. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010;30:245-257.
50. Planagumà A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, Bleecker ER, Curran-Everett D, Erzurum SC, Calhoun WJ, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-582.